New development of the research daily NASH test: Genfit terminated the test CymaBay shelving.

2020.07.24 Research and Development NEWS: Favipiravir treatment of light and moderate new crown patients small stage 3 clinical reach the main endpoint; We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original text) The latest development in the nash field: Genfit Termination Phase III Trial CymaBay Clinical Shelving Genfit recently updated the company's strategy: Stop PPAR alpha/exciting agent elafibranor treatment of adult NASH and fibrosis PHASE III RESOLVE-IT clinical trial.
, CymaBay announced that the FDA has lifted the clinical shelving of PPAR's agonists seladelpar in nash, PBC, primary sclerosing chochocarditis (PSC).
Favipiravir treatment of mild, moderate new crown patients small stage 3 clinical main endpoint recently, Glenmark developed the antiviral drug favipiravir generic FabiFlu, in a Phase 3 clinical study showed accelerated COVID-19 mild to moderate symptoms of patients to restore healthy cycle. The latest results, released by
Glenmark, show that favipiravir increased the virus clearance rate by 28.6 percent to the primary endpoint compared to the placebo.
JAK inhibitors to treat chronic transplant anti-host disease to the clinical end of Phase 3 Incyte announced that the JAK1/2 inhibitor Jakafi, developed jointly with Novartis, reached the primary endpoint in stage 3 clinical studies in the treatment of moderate or severe steroid refractive or steroid-dependent chronic transplant anti-host patients, with a better total remission rate (ORR) in week 24 than the best available therapy (BAT).
the first patient-administered drug of herb Octopus "first-in-class" brain tumor completed the first patient administration 23, herb Octopus announced that it had completed the first patient administration in a phase 1 clinical trial of the new drug NBQ72S in the treatment of advanced malignancies.
NBQ72S is a new type of dual-function small molecule drug targeting human L-type amino acid transporter protein 1, which is the world's first new drug (first-in-class), to develop and treat malignant tumors such as brain tumors.
Paige BioGLP-1 Receptor Agonisad "Polyglycol Essenapeptide" launched Phase 3 Clinical 23, Paige Bio-Independent research of a class 1 innovative drug - long-acting GLP-1 receptor agonists PB-119 "polyethylene glycol eseninapeptide injection" launched a Phase III clinical study to evaluate PB-119 on the effectiveness and safety of treated untreated type 2 diabetes.
"Drug Approval" Collon Pharmaceuticals "Hydrochloric acid delineation of non-tablets" first imitation approved 24, Collon Pharmaceuticals 4 types of generic hydrochloric acid dealinate non-tablets approved by the State Drug Administration for listing, for the first domestic imitation.
Qilu Apixaban film review 24, Qilu Pharmaceutical and Nanjing Zhengda Qing according to the new 4 categories of declared Apixaban tablets were approved by the State Drug Administration for listing, as the same through the consistency evaluation.
National Pharmaceutical Group hydrochloric acid right metomidin injection over evaluation of national pharmaceutical group industry Co., Ltd. Langfang Branch declared three types of generic drug hydrochloric acid right mememimidin injection today was approved by the State Drug Administration for listing, as is the same as through the consistency evaluation.
Nanjing Zhengda Qing 3 generic drugs were approved on the 24th, Nanjing Zhengda Qing 3 4 types of generic drugs (Apixa ban tablets, acetic acid tofati cloth tablets, injection of hydrochloric acid Idabi Star) approved by the State Drug Administration for listing, as the same through the consistency evaluation.
, Beijing-New Pharmaceuticals "Paskso Hydrochloric Acid Slow Release Tablet" was the first approved today, Beijing New Pharmaceuticals 4 types of generic drug Praxote slow release tablets approved by the State Drug Administration for listing, the first domestic manufacturer of the drug approved, and as the same through the consistency evaluation.
stone pharmaceutical group antidepressant "hydrochloric acid luosidine intestinal capsules" approved on the 24th, stone pharmaceutical group according to the new 4 categories of hydrochloric acid losistine intestinal lysis capsule listing application obtained the Approval of the State Drug Administration for listing, as is the same as through the consistency evaluation.
Shangjian biological CD38 single anti-declaration clinical and received the latest nMPA publicity, Shangjian bio-class 1 new drug CD38 single anti-declaration clinical and accepted.
this is the company's second product to submit a clinical trial to NMPA, the first of which, PD-1 antibodies, was approved for clinical use in November 2018.
innovative cardiomyopathy targeted therapy by the FDA breakthrough therapy identified MyoKardia announced that the U.S. FDA has awarded the company to develop the mavacamten breakthrough therapy for the treatment of symptomatic, obstructive hypertrophy cardiomyopathy.
Mavacamten is an innovative oral myocardial myoglobin deflator that is expected to reduce the symptoms of excessive cardiac contraction in patients.
Cornerstone Pharmaceuticals PD-1 antibodies by the U.S. FDA awarded orphan drug eligibility Cornerstone Pharmaceuticals announced that the U.S. FDA has awarded its PD-1 antibody CS1003 orphan drug eligibility for the treatment of liver cell cancer.
CS1003 is one of the products of tumor immunoskeleton in Keystone Pharmaceuticals, and has carried out a number of clinical studies on joint treatment, of which CS1003 joint levalinib is the first line of treatment of patients with advanced liver cancer, the global multi-center 3 registered clinical research is in the group.
long-chain fatty acid oxidation metabolic disease drug Dojolvi recently launched in the United States, Ultragenyx announced that Dojolvi is now on the market, the drug was approved by the U.S. FDA at the end of June this year as a source of calories and fatty acids, for the treatment of molecularly tested long-chain fatty acid oxidation metabolic disease (LC-FAOD) in children and adult patients.
Dojolvi was the first FDA-approved drug to treat LC-FAOD, marking a major milestone in the treatment of the disease.
Xinlitai Repamycin Drug Removal Vertebral Arterial Stent System obtained medical device registration certificate Xinlitai issued a notice that the company's subsidiary Yallen Bio received the State Drug Administration approved the issuance of the "Rapamycin drug removal vertebral arterial stent system" (Maurora ®) "medical device registration certificate."
the product is a combination of severely clinically proven reperacycin drugs that are clinically proven in the intracranial artery and vertebral artery, which is suitable for the stenosis expansion of the excranial excranial segment of the symptomatic vertebral artery.
.